JP2016521258A5 - - Google Patents

Download PDF

Info

Publication number
JP2016521258A5
JP2016521258A5 JP2016503422A JP2016503422A JP2016521258A5 JP 2016521258 A5 JP2016521258 A5 JP 2016521258A5 JP 2016503422 A JP2016503422 A JP 2016503422A JP 2016503422 A JP2016503422 A JP 2016503422A JP 2016521258 A5 JP2016521258 A5 JP 2016521258A5
Authority
JP
Japan
Prior art keywords
hemoglobin
lysine
pao
conjugate
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503422A
Other languages
English (en)
Japanese (ja)
Other versions
JP6657070B2 (ja
JP2016521258A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/030569 external-priority patent/WO2014145755A1/en
Publication of JP2016521258A publication Critical patent/JP2016521258A/ja
Publication of JP2016521258A5 publication Critical patent/JP2016521258A5/ja
Application granted granted Critical
Publication of JP6657070B2 publication Critical patent/JP6657070B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503422A 2013-03-15 2014-03-17 ポリアルキレンオキシド吉草酸ヘモグロビン接合体 Active JP6657070B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361801016P 2013-03-15 2013-03-15
US61/801,016 2013-03-15
PCT/US2014/030569 WO2014145755A1 (en) 2013-03-15 2014-03-17 Polyalkylene oxide valerate hemoglobin conjugates

Publications (3)

Publication Number Publication Date
JP2016521258A JP2016521258A (ja) 2016-07-21
JP2016521258A5 true JP2016521258A5 (cg-RX-API-DMAC7.html) 2017-04-20
JP6657070B2 JP6657070B2 (ja) 2020-03-04

Family

ID=51538084

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503422A Active JP6657070B2 (ja) 2013-03-15 2014-03-17 ポリアルキレンオキシド吉草酸ヘモグロビン接合体

Country Status (10)

Country Link
US (1) US10821158B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968597B1 (cg-RX-API-DMAC7.html)
JP (1) JP6657070B2 (cg-RX-API-DMAC7.html)
KR (1) KR102238718B1 (cg-RX-API-DMAC7.html)
CN (1) CN105188761B (cg-RX-API-DMAC7.html)
AU (1) AU2014232540B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015023233A8 (cg-RX-API-DMAC7.html)
CA (1) CA2906878C (cg-RX-API-DMAC7.html)
MX (1) MX373193B (cg-RX-API-DMAC7.html)
WO (1) WO2014145755A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10506829B2 (en) 2016-02-26 2019-12-17 Freelander Innovations USA, LLC System and method for a vaporizer
EP3655019A4 (en) 2017-07-18 2021-04-21 Virtech Bio, Inc. BLOOD SUBSTITUTES INCLUDING HEMOGLOBIN AND METHODS OF MANUFACTURING
GB201721503D0 (en) * 2017-12-20 2018-01-31 Univ Essex Modified globin proteins
CA3149234A1 (en) * 2019-08-29 2021-03-04 Kwok Chu Butt Thiosuccinyl-crosslinked hemoglobin analogs and methods of use and preparation thereof
WO2021110127A1 (en) * 2019-12-06 2021-06-10 Cheer Global Limited Method of treating inflammatory bowel disease
US11857605B2 (en) 2021-03-01 2024-01-02 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
GB8710598D0 (en) 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US6054427A (en) * 1997-02-28 2000-04-25 The Regents Of The University Of California Methods and compositions for optimization of oxygen transport by cell-free systems
KR100316154B1 (ko) 1999-03-26 2001-12-12 노광 폴리에틸렌글리콜-헤모글로빈 결합체
DE10031744A1 (de) * 2000-06-29 2002-01-17 Sanguibio Tech Ag Mit Blutplasma verträgliche, vernetzte und mit Polyalkylenoxiden konjugierte Säugetierhämoglobine als künstliche medizinische Sauerstoffträger, ihre Herstellung und ihre Verwendung
DE10031740A1 (de) 2000-06-29 2002-02-14 Sanguibio Tech Ag Künstliche Sauerstoffträger aus vernetztem modifizierten Human- oder Schweinehämoglobin mit verbesserten Eigenschaften, Verfahren zu ihrer technisch einfachen Herstellung aus gereinigtem Material in hohen Ausbeuten, sowie deren Verwendung
US20030153491A1 (en) 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
DE10220992A1 (de) 2002-05-11 2003-12-04 Sanguibiotech Ag Verwendung eines oder mehrerer Sauerstoffträger, ausgewählt aus Hämoglobin, Myoglobin und Derivaten hiervon zur Behandlung einer Organfunktionsstörung infolge eines akuten Versorgungsmangels und zur Behandlung/Vermeidung einer Gewebeschädigung infolge einer solchen Störung
CN100337689C (zh) 2002-07-24 2007-09-19 弗·哈夫曼-拉罗切有限公司 聚亚烷基二醇酸加合物
US20040072729A1 (en) 2002-10-10 2004-04-15 Sunbio Inc. High oxygen affinity PEG-hemoglobin as treatment for brain stroke
AU2003299700B2 (en) * 2002-12-23 2009-03-26 Albert Einstein College Of Medicine Of Yeshiva University Modified hemoglobin and methods of making same
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
DE10352692A1 (de) 2003-11-12 2005-06-23 Sanguibiotech Gmbh Verwendung hypo-onkotischer Lösungen in das Blut addierbarer, hyperpolymerer Hämoglobine zur Behandlung eines Lungenödems
EP1863503B1 (en) 2005-03-07 2019-05-22 Sangart, Inc. Composition for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
DK3266463T3 (da) 2009-06-09 2024-01-08 Prolong Pharmaceuticals Llc Hæmoglobinsammensætninger
WO2013151776A1 (en) 2012-04-03 2013-10-10 Sangart, Inc. Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins

Similar Documents

Publication Publication Date Title
JP2015514718A5 (cg-RX-API-DMAC7.html)
CN104411807B (zh) 琥珀酰亚胺活化型硝酰化合物及其用于蛋白质硝酰化的使用方法
CN104395391A (zh) 双重衍生化的壳聚糖纳米粒子以及制造和使用其用于体内基因转移的方法
JP2015514086A5 (cg-RX-API-DMAC7.html)
JP6668515B2 (ja) ジアスピリン架橋pegヘモグロビン
JP2013528229A5 (cg-RX-API-DMAC7.html)
US20080188399A1 (en) Drug-Polymer Conjugates Coupled to a Peptidic Carrier
US20070166278A1 (en) Novel g-csf conjugates
WO2012067138A1 (ja) 新規なシチジン系代謝拮抗剤の高分子誘導体
JP6657070B2 (ja) ポリアルキレンオキシド吉草酸ヘモグロビン接合体
JP2011507913A5 (cg-RX-API-DMAC7.html)
JP6358797B2 (ja) 癌を処置するためのウミロリムスおよびその誘導体の使用
JP5281358B2 (ja) 高分子、経上皮吸収促進剤、及び医薬用製剤
US20230123697A1 (en) Therapeutic patch for gastrointestinal tract and method of manufacturing same
JP7773169B2 (ja) ポリオキサゾリン結合アルブミン、人工血漿増量剤及び出血ショックの蘇生液
US20210401949A1 (en) Hemoglobin Derivative Co-conjugated with Fatty Acid-linked PEG and Alkoxy PEG as a Blood Substitute
JPS63208523A (ja) 酸素運搬剤
RU2025117117A (ru) Фармацевтическая композиция для предупреждения или лечения заболевания "трансплантат против хозяина", содержащая производное GLP-2 или его конъюгат длительного действия
HK1219053B (en) Polyalkylene oxide valerate hemoglobin conjugates
EP2508199A1 (en) Melanocyte-stimulation hormone for suppressing inflammation reactions in hemodialysis
EP2508198A1 (en) Peptides for suppressing inflammation reactions in hemodialysis